Voyager Therapeutics

Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.

Company Growth (employees)

Type

Public

Cambridge, US

Founded

2014

Size (employees)

52 (est)

Website

voyagertherapeutics.com

Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People at Voyager Therapeutics

Mark Kay

Founder

Phillip D. Zamore

Founder

Guangping Gao

Founder

Krystof Bankiewicz

Founder

Jeff Goater

Vice President of Business Development

James Geraghty

Interim Chief Business Officer

Voyager Therapeutics Office Locations

Voyager Therapeutics has an office in Cambridge

Cambridge, US (HQ)

75 Sidney St

Voyager Therapeutics Data and Metrics

Voyager Therapeutics Financial Metrics

Voyager Therapeutics's revenue was reported to be $14.2 m in FY, 2016

Summary

USD

Voyager Therapeutics's current market capitalization is $244.8 m.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2015	FY, 2016
Revenue	17.3 m	14.2 m
Revenue growth, %		(18%)
EBITDA	(20.5 m)	(41.3 m)
EBITDA margin, %	(118%)	(290%)
Net Income	(3.8 m)	(40.2 m)

Quarterly

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2015	FY, 2016
Accounts Receivable		826 m
Current Assets	195.9 m	178.8 m
PP&E	3.2 m	7.9 m
Total Assets	229.5 m	189.6 m
Accounts Payable	612 k	550 k
Current Liabilities	23.9 m	13.8 m
Total Liabilities		53.6 m
Additional Paid-in Capital	219.1 m	226 m
Retained Earnings	(49.8 m)	(90 m)

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	66.5 m	33.9 m	67 m
Current Assets	108.6 m	205.7 m	205.5 m	193 m	161.1 m
PP&E	3.3 m	3.6 m	3.6 m	4.3 m	10.1 m
Total Assets	166.4 m	220 m	209.8 m	202 m	175.1 m
Accounts Payable	541 k	1.7 m	454 k	787 k	557 k
Current Liabilities	23.4 m	23.1 m	19.8 m	19.4 m	11.1 m
Additional Paid-in Capital		220.6 m	222 m	223.8 m	229 m
Retained Earnings	(47.2 m)	(57 m)	(66.3 m)	(75.3 m)	(106.7 m)

Cash Flow

Annual

USD	FY, 2015	FY, 2016
Net Income	(3.8 m)	(40.2 m)
Depreciation and Amortization	600 k	612 k
Inventories	(234 k)	(847 k)
Accounts Payable	950 k	(62 k)
Cash From Operating Activities	(2.7 m)	(42.5 m)
Purchases of PP&E	(1 m)	(5 m)
Cash From Investing Activities	(194.8 m)	47.3 m
Cash From Financing Activities	2.9 m	514 k

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(22.4 m)	(7.2 m)	(16.5 m)	(25.5 m)	(16.6 m)
Depreciation and Amortization	436 k	136 k	288 k	448 k	317 k
Accounts Payable	(1 m)	1.1 m	(158 k)	175 k	280 k
Cash From Operating Activities	50.9 m	(9.5 m)	(19.2 m)	(29.4 m)	(14.3 m)
Purchases of PP&E	(909 k)	(460 k)	(657 k)	(1.2 m)	(2.9 m)
Cash From Investing Activities	(95.2 m)	12.1 m	54.8 m	61.4 m	20.7 m
Cash From Financing Activities	103.8 m	4 k	93 k	146 k	602 k